Maxime Dely: Does Whole Blood Deserve a Greater Role in Modern Transfusion Medicine?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post onย LinkedIn:
”๐ฃ๐น๐ฎ๐๐บ๐ฎ, ๐ฝ๐น๐ฎ๐๐ฒ๐น๐ฒ๐๐, ๐ฟ๐ฒ๐ฑ ๐ฏ๐น๐ผ๐ผ๐ฑ ๐ฐ๐ฒ๐น๐น๐: ๐ฆ๐ต๐ผ๐๐น๐ฑ ๐๐ฒ ๐ธ๐ฒ๐ฒ๐ฝ ๐๐ฒ๐ฝ๐ฎ๐ฟ๐ฎ๐๐ถ๐ป๐ด… ๐ผ๐ฟ ๐๐๐ฎ๐ฟ๐ ๐ฟ๐ฒ๐๐ต๐ถ๐ป๐ธ๐ถ๐ป๐ด?
For decades, transfusion medicine has relied on a widely accepted principle: separating donated blood into components (red blood cells, plasma, platelets) to optimize each donation and target specific clinical needs.
๐๐ฉ๐ช๐ด ๐ฎ๐ฐ๐ฅ๐ฆ๐ญ ๐ฉ๐ข๐ด ๐ด๐ข๐ท๐ฆ๐ฅ ๐ฎ๐ช๐ญ๐ญ๐ช๐ฐ๐ฏ๐ด ๐ฐ๐ง ๐ญ๐ช๐ท๐ฆ๐ด โ ๐ฃ๐ถ๐ต ๐ช๐ด ๐ช๐ต ๐ด๐ต๐ช๐ญ๐ญ ๐ต๐ฉ๐ฆ ๐ฃ๐ฆ๐ด๐ต ๐ข๐ฑ๐ฑ๐ณ๐ฐ๐ข๐ค๐ฉ ๐ต๐ฐ๐ฅ๐ข๐บ?
In certain clinical settings โ trauma, surgery, ICU โ patients often receive all three components separately.
In effect, ๐๐ฒโ๐ฟ๐ฒ ๐ฟ๐ฒ๐ฎ๐๐๐ฒ๐บ๐ฏ๐น๐ถ๐ป๐ด ๐๐ต๐ผ๐น๐ฒ ๐ฏ๐น๐ผ๐ผ๐ฑ, at the cost of logistical complexity, higher costs, and sometimes increased transfusion-related risks.
Shortages, overtransfusion, component waste, and supply chain strain are all issues pushing practitioners to reassess.
In response, ๐บ๐ถ๐น๐ถ๐๐ฎ๐ฟ๐ ๐ฎ๐ป๐ฑ ๐๐ฟ๐ฎ๐๐บ๐ฎ ๐๐ฒ๐ฟ๐๐ถ๐ฐ๐ฒ๐ ๐ฎ๐ฟ๐ฒ ๐ฟ๐ฒ๐ถ๐ป๐๐ฟ๐ผ๐ฑ๐๐ฐ๐ถ๐ป๐ด ๐น๐ฒ๐๐ธ๐ผ๐ฟ๐ฒ๐ฑ๐๐ฐ๐ฒ๐ฑ ๐๐ต๐ผ๐น๐ฒ ๐ฏ๐น๐ผ๐ผ๐ฑ, which is simpler to store and administer, and often more physiologically effective in critical care scenarios.
At the same time, predictive tools, AI-based algorithms, and innovative products (customized components, artificial blood, freeze-dried plasma) are paving the way toward ๐บ๐ผ๐ฟ๐ฒ ๐ฝ๐ฒ๐ฟ๐๐ผ๐ป๐ฎ๐น๐ถ๐๐ฒ๐ฑ, ๐ฒ๐ณ๐ณ๐ถ๐ฐ๐ถ๐ฒ๐ป๐, ๐ฎ๐ป๐ฑ ๐๐ฎ๐ฟ๐ด๐ฒ๐๐ฒ๐ฑ ๐๐ฟ๐ฎ๐ป๐๐ณ๐๐๐ถ๐ผ๐ป ๐๐๐ฟ๐ฎ๐๐ฒ๐ด๐ถ๐ฒ๐.
So should we keep separating blood by default? Or tailor our practices to real-world needs, resource constraints, and clinical outcomes?
Rethinking doesn’t mean rejecting. It means ๐ฒ๐๐ผ๐น๐๐ถ๐ป๐ด ๐ฎ ๐ต๐ถ๐๐๐ผ๐ฟ๐ถ๐ฐ ๐บ๐ผ๐ฑ๐ฒ๐น toward greater agility, precision, and clinical relevance.
Whatโs your view? Does whole blood deserve a greater role in modern transfusion medicine?”
Stay informed with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payรกn Pernรญa on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heartโค Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Cรดme Bommier: Burnout Is Common Among Hematology Professionals